In the past week, AKBA stock has gone down by -2.92%, with a monthly decline of -12.50% and a quarterly surge of 34.45%. The volatility ratio for the week is 4.45%, and the volatility levels for the last 30 days are 5.48% for Akebia Therapeutics Inc.. The simple moving average for the past 20 days is -5.72% for AKBA’s stock, with a -3.06% simple moving average for the past 200 days.
Is It Worth Investing in Akebia Therapeutics Inc. (NASDAQ: AKBA) Right Now?
Additionally, the 36-month beta value for AKBA is 0.77. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AKBA is 199.72M and currently, short sellers hold a 9.54% ratio of that float. The average trading volume of AKBA on September 27, 2024 was 2.58M shares.
AKBA) stock’s latest price update
Akebia Therapeutics Inc. (NASDAQ: AKBA) has experienced a rise in its stock price by 0.76 compared to its previous closing price of 1.32. However, the company has seen a fall of -2.92% in its stock price over the last five trading days. prnewswire.com reported 2024-09-05 that Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care Trial aims to build a body of real-world evidence to understand the potential benefits of treating patients with Vafseo CAMBRIDGE, Mass., Sept. 5, 2024 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, today announced plans to begin a collaborative clinical trial of recently approved Vafseo.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at -4.14% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.37% of loss for the given period.
Volatility was left at 5.48%, however, over the last 30 days, the volatility rate increased by 4.45%, as shares sank -13.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.67% lower at present.
During the last 5 trading sessions, AKBA fell by -2.92%, which changed the moving average for the period of 200-days by +17.70% in comparison to the 20-day moving average, which settled at $1.4008. In addition, Akebia Therapeutics Inc. saw 7.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Hadas Nicole R., who sale 12,016 shares at the price of $1.26 back on May 13 ’24. After this action, Hadas Nicole R. now owns 651,243 shares of Akebia Therapeutics Inc., valued at $15,140 using the latest closing price.
Dahan Michel, the SVP, Chief Operating Officer of Akebia Therapeutics Inc., sale 34,840 shares at $1.26 during a trade that took place back on May 13 ’24, which means that Dahan Michel is holding 672,092 shares at $43,898 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.62 for the gross margin
The net margin for Akebia Therapeutics Inc. stands at -0.23. The total capital return value is set at -0.31. Equity return is now at value -554.87, with -17.07 for asset returns.
Based on Akebia Therapeutics Inc. (AKBA), the company’s capital structure generated 1.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at -2.91. The interest coverage ratio of the stock is -4.72.
Currently, EBITDA for the company is -4.23 million with net debt to EBITDA at 26.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.98. The receivables turnover for the company is 5.86for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In conclusion, Akebia Therapeutics Inc. (AKBA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
